December 30, 2018
Odan Laboratories Ltd., a fast growing Canadian pharmaceutical company, is proud to announce that it has acquired Verlyx Pharma Inc. (“Verlyx”), a Montreal based clinical stage Biopharmaceutical company, for the development and commercialization of its lead compound VLX103 and its analogs in GI.
VLX103 and its analogs appear to be potentially active in modulating the pathogenic pathways involving Lipopolysaccharides (LPS) in Inflammatory Bowel Disease (IBD), specifically Ulcerative Colitis (UC), Irritable Bowel Syndrome (IBS), IBS-D and post infections IBS as well as celiac disease. Consequently, these disease states have been selected for pharmacological exploration of the Verlyx compounds. In this context, 2 analogs of VLX103 as well as the original compound are proposed in the pre-clinical development program.
“With the acquisition of Verlyx, Odan continues to expand and diversify its R&D activities,” expressed Howard Kaminsky, President of Odan. “We are confident in the potential of Verlyx’s VLX103 and its analogs to be profitable in the future to Odan.”